fexagratinib   Click here for help

GtoPdb Ligand ID: 7707

Synonyms: ABSK-091 | ABSK091 | AZD-4547 | KB-74810
PDB Ligand
Compound class: Synthetic organic
Comment: AZD4547 is a fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor, investigated as a potential treatment for solid tumours. This compound is now included in AstaZeneca's Open Innovation Pharmacology Toolbox. The INN fexagratinib (proposed list 129; August 2023) has been matched to AZD4547.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 91.51
Molecular weight 463.26
XLogP 4.5
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2CC(C)NC(C2)C)cc(c1)OC
Isomeric SMILES COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2C[C@H](C)N[C@@H](C2)C)cc(c1)OC
InChI InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
InChI Key VRQMAABPASPXMW-HDICACEKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
AZD4547 was progressed as a clinical candidate for the treatment of various advanced solid tumour types.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05775874 A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC Phase 2 Interventional Abbisko Therapeutics Co, Ltd
NCT05086666 A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 Phase 1/Phase 2 Interventional Abbisko Therapeutics Co, Ltd
NCT02965378 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Phase 2/Phase 3 Interventional SWOG Cancer Research Network